Design, synthesis and bioactivity of indobufen derivatives
Danli Yuan1, Liping Chen2, Xin Huang1
1Gannan Medical University Ganzhou 341000 China.
Abstract:
Osteoporosis is characterized by excessive osteoclast-mediated bone resorption, a process that can be amplified by inflammatory cues within the bone microenvironment. Targeting the inflammation-osteoclast axis has therefore emerged as a promising strategy for preventing pathological bone loss. Here, a series of indobufen-modified derivatives were rationally designed and synthesized, and their biological activities were evaluated through a stepwise in vitro screening workflow. Early inflammatory profiling in fibroblast-like synoviocytes (FLS) identified compound A1 as a lead candidate with pronounced suppression of pro-inflammatory mediators and matrix-degrading enzymes. In a RANKL-induced RAW264.7 osteoclastogenesis model, A1 inhibited osteoclast maturation at non-cytotoxic concentrations, markedly reducing the expression of osteoclast functional proteins (MMP9 and cathepsin K) and disrupting F-actin ring formation and multinucleation. Collectively, these findings demonstrate that indobufen scaffold modification can yield small molecules with dual anti-inflammatory and anti-osteoclastogenic activities and highlight A1 as a promising lead compound for the development of therapeutics targeting osteoporosis and inflammation-associated bone loss.
Insights
New indobufen derivatives show promise for treating osteoporosis. Compound A1 effectively reduces inflammation and inhibits osteoclast activity, offering a dual approach to prevent bone loss.
Area of Science:
- Biochemistry
- Pharmacology
- Immunology
Background:
- Osteoporosis involves excessive bone resorption driven by osteoclasts, often exacerbated by inflammation.
- Targeting the inflammation-osteoclast pathway is a key strategy for preventing bone loss.
Purpose of the Study:
- To design and synthesize novel indobufen derivatives.
- To evaluate the anti-inflammatory and anti-osteoclastogenic potential of these derivatives.
- To identify lead compounds for osteoporosis therapeutics.
Main Methods:
- Rational design and synthesis of indobufen derivatives.
- In vitro screening, including inflammatory profiling in fibroblast-like synoviocytes (FLS).
- Assessment of osteoclastogenesis in a RANKL-induced RAW264.7 model, evaluating osteoclast markers and function.
Main Results:
- Compound A1 demonstrated significant suppression of pro-inflammatory mediators and matrix-degrading enzymes in FLS.
- A1 inhibited osteoclast maturation at non-cytotoxic levels, reducing key proteins like MMP9 and cathepsin K.
- A1 disrupted osteoclast F-actin ring formation and multinucleation.
Conclusions:
- Indobufen scaffold modification can generate small molecules with dual anti-inflammatory and anti-osteoclastogenic properties.
- Compound A1 is a promising lead candidate for developing therapeutics against osteoporosis and inflammation-associated bone loss.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:26Drug Discovery: Overview